查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2028 年缺鐵性貧血治療市場預測——按療法、治療領域、年齡、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1273281

2028 年缺鐵性貧血治療市場預測——按療法、治療領域、年齡、最終用戶和地區進行的全球分析

Iron Deficiency Anemia Therapy Market Forecasts to 2028 - Global Analysis By Therapy, Therapy Area, Age, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC，全球缺鐵性貧血 (IDA) 治療市場將在 2022 年達到 18.7 億美元，到 2028 年將達到 23.6 億美元，預計複合年增長率為 3.95%在預測期間。

缺鐵性貧血 (IDA) 是當血液中沒有足夠的健康紅細胞時發生的一種病症。 紅細胞有助於儲存和運輸血液中的氧氣，由鐵製成。 紅細胞為人體組織提供氧氣。 紅細胞含有鐵，這是合成血紅蛋白所必需的。 如果您沒有足夠的血紅蛋白，您的身體可能無法獲得足夠的氧氣。 水果、肉類、蔬菜和穀物等含鐵量高的食物有助於治療和預防。 服用維生素 C 有助於預防缺鐵。

根據 2021 年 11 月發布的《全球營養報告》，印度 15-49 歲的女性中，超過半數，約佔人口的 53%，被發現患有貧血。

市場動態：

驅動程序

缺鐵性貧血患病率增加

缺鐵性貧血 (IDA) 是一個全球性的健康問題。 缺鐵性貧血影響不同年齡和性取向的人。 然而，據說十幾歲的女孩更容易受到影響。 鐵需求增加、每月出血、疾病和蟲害可能是罪魁禍首。 不食用富含鐵的食物（如肉類）的人更容易患缺鐵性貧血。 頻繁獻血和營養缺乏正在推動對治療缺鐵性貧血 (IDA) 藥物的需求。

約束

缺乏足夠的測試

貧血可能由多種健康問題引起。 沒有足夠的測試來診斷這種情況。 貧血往往被低估和治療不足。 它通常通過鐵補充劑進行管理，並記錄為單一診斷。 其症狀和指標的頻率和嚴重程度各不相同。 如果管理不當，可能會導致心力衰竭和死亡。 這些因素阻礙了市場需求。

機會

癌症發病率增加

癌症患者更容易患上缺鐵性貧血。 肺癌和乳腺腫瘤已被證明在實體瘤中貧血的頻率最高。 貧血是由多發性骨髓瘤、白血病和淋巴瘤等血癌產生的異常血細胞引起的。 這些疾病會削弱免疫系統。 化療和放療等癌症治療也會加劇癌症患者的貧血。 從這方面來看，市場開闢了更多的可能性。

威脅：

鐵補充劑的副作用

攝入含鐵藥物會產生噁心、嘔吐、胃痛、便秘和食慾不振等不良反應。 這些藥物還會引起過量症狀，例如疲勞、虛弱、呼吸淺或急促、皮膚發青、抽筋、皮膚蒼白和指甲蒼白。 所有這些不利影響都阻礙了市場的擴張。

COVID-19 的影響：

COVID-19 大流行對醫療保健系統產生了巨大影響，嚴重影響了感染和未感染 COVID-19 的人，以及停止治療、管理和確保資源的程序等。 COVID-19 患者貧血的流行導致對鐵療法和其他貧血相關治療的需求增加。

兒科領域預計將成為預測期內最大的領域

兒科部門估計有良好的增長。 兒童經常缺鐵。 缺鐵有多種形式，從輕度到缺鐵性貧血。 兒童的生長發育可能會受到未經治療的缺鐵症的影響。 兒童缺鐵通常由營養缺乏、早產和低出生體重引起。 血紅蛋白和血細胞比容診斷結果的改進正在推動這一領域的需求。

在預測期內，預計口服鐵製劑的複合年增長率最高。

口服鐵補充劑由於恢復鐵平衡的能力強，預計在預測期內將以最快的複合年增長率增長。 應使用口服鐵補充劑至少 3 至 6 個月，以補充鐵儲備並使鐵蛋白水平正常化。 通過增加體內鐵和血紅蛋白的含量，它可以緩解患者的症狀。 口服鐵片含有不同水平的元素鐵。

市場份額最高的地區

由於其發達的醫療保健系統，預計在預測期內北美將佔據最大的市場份額。 該地區醫療基礎設施發達，競爭者少，因此對缺鐵性貧血治療藥物的需求不斷增加。 此外，消費者對女性健康問題意識的增強和技術的進步正在推動該地區的市場擴張。

複合年增長率最高的地區：

由於人口增長和政府舉措，預計亞太地區在預測期內的複合年增長率最高。 這個地區的女性人口非常多。 該地區的市場需求受到醫療保健成本上升、政府支持醫療保健行業的努力以及對 IDA 治療需求不斷增長的推動。

主要發展：

2023 年 2 月，Rockwell Medical, Inc. 宣布與美國最大的專業護理機構透析提供商 Concerto Renal Services（“Concerto”）簽訂了為期三年的產品採購協議。 根據協議條款，羅克韋爾醫療公司將通過三年承諾（包括最低供應和採購條款）作為液體和乾燥酸和碳酸氫鹽濃縮物的主要供應商供應 Concerto。

2022 年 9 月，Alkem 實驗室宣布，現成的細胞治療產品 StemOne 已獲得印度藥品監管局 (DCGI) 的監管批准，可在印度上市。 該產品由 Alkem Laboratories 與 Stempeutics 合作推出，用於治療膝骨關節炎，這是一種關節退行性疾病。

2022 年 3 月，Teva Pharmaceutical Industries Ltd. 的美國子公司 Teva Pharmaceuticals 推出了規格為 5 毫克、10 毫克、15 毫克和 25 毫克的 RevlimidR 1（來那度胺膠囊）的第一個仿製藥。宣佈在美國上市。

本報告內容

  • 區域和國家/地區細分市場份額評估
  • 向新進入者提出戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 市場驅動因素（市場趨勢、制約因素、機遇、威脅、挑戰、投資機會、建議）。
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局映射關鍵共同趨勢。
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 映射最新技術進步的供應鏈趨勢

免費定制優惠：

購買此報告的客戶將獲得以下免費定制選項之一：

  • 公司簡介
    • 其他市場參與者的綜合概況（最多 3 家公司）
    • 主要參與者的 SWOT 分析（最多 3 家公司）
  • 區域細分
    • 根據客戶的要求對主要國家/地區的市場估計/預測/複合年增長率（注意：基於可行性檢查）。
  • 競爭基準
    • 根據產品組合、區域影響力和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究來源
    • 二級研究來源
    • 假設

第三章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球缺鐵性貧血 (IDA) 治療市場：按治療分類

  • 母體鐵療法
  • 口服鐵療法
  • 紅細胞輸注療法
  • 其他治療

第 6 章全球缺鐵性貧血 (IDA) 治療市場：按治療領域分類

  • 充血性心力衰竭 (CHF)
  • 腎臟科、婦產科、
  • 腫瘤學
  • 炎症性腸病
  • 其他治療領域

第 7 章全球缺鐵性貧血 (IDA) 治療市場：按年齡分類

  • 對於老年人
  • 成人
  • 兒科

第 8 章。全球缺鐵性貧血 (IDA) 治療市場：按最終用戶分類

  • 診所
  • 醫院
  • 家庭保健

第 9 章全球缺鐵性貧血 (IDA) 治療市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東和非洲地區

第10章主要發展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Vifor Pharma Ltd
  • Teva Pharmaceutical Industries Ltd
  • Sanofi
  • Pfizer Inc
  • Novartis AG
  • Mylan N.V.
  • Lupin
  • Zydus Cadila
  • GlaxoSmithKline plc
  • Fresenius SE & Co. KGaA
  • F. Hoffmann-La Roche Ltd
  • Shield Therapeutics
  • Pharmacosmos A/S
  • AMAG Pharmaceuticals
  • Akebia Therapeutics, Inc
  • AbbVie Inc.
  • Hikma Pharmaceuticals plc
  • Alkem Laboratiories
  • Advanz Pharmaceutical
  • Rockwell Medical, Inc
Product Code: SMRC22826

According to Stratistics MRC, the Global Iron Deficiency Anemia (IDA) Therapy Market is accounted for $1.87 billion in 2022 and is expected to reach $2.36 billion by 2028 growing at a CAGR of 3.95% during the forecast period. Iron Deficiency Anemia (IDA) is a condition that occurs when there are not enough healthy red blood cells in the blood. Red blood cells, which aid in storing and transporting oxygen in the blood, are created using iron. RBCs provide oxygen to human tissues. Red blood cells contain iron, which is necessary for haemoglobin synthesis. An inadequate amount of haemoglobin may indicate that the body is not receiving enough oxygen. Foods rich in iron, such as fruits, meat, vegetables, and cereals, can be used to treat or prevent it. Consuming vitamin C can help prevent iron shortage.

According to the Global Nutrition Report, published in November 2021, it has been found that over half of Indian women aged between 15 - 49 years that is about 53% of the population are anemic.

Market Dynamics:

Driver:

Increased prevalence of iron deficiency anaemia

Iron Deficiency Anaemia (IDA) is a global health problem. It involves people of various ages and sexual orientations. However, teenage females are more susceptible to it. Increased iron need, monthly blood loss, illness, and worm infestation might be the causes. People who don't consume meat or other foods high in iron may be more susceptible to iron deficiency anaemia. Frequent blood donations and nutritional deficiencies are raising the demand for Iron Deficiency Anaemia (IDA) Therapies.

Restraint:

Lack of adequate testing

Anaemia may develop from a variety of different health issues. There aren't enough tests available to diagnose this condition. Anaemia tends to be neither properly assessed nor treated. It is commonly managed with iron supplements and recorded as a standalone diagnosis. The frequency and severity of its symptoms and indicators differ. It can cause heart failure or death if not adequately managed. These elements hinder the market demand.

Opportunity:

Growing incidence of cancer

Cancer patients are becoming more likely to have iron deficient anaemia. Lung and breast tumours have been shown to have the greatest anaemic frequency among solid tumours. Anaemia is caused by the aberrant blood cells that hematologic cancers like multiple myeloma, leukaemia, and lymphoma create. The immune system is weakened by these illnesses. Cancer treatments like chemotherapy and radiation worsen anaemia in cancer patients. These aspects create more prospects to the market.

Threat:

Side effects of iron supplements

Consuming iron-containing medications causes negative effects such as nausea, vomiting, stomach aches and constipation and issues with appetite. These medications can also cause overdose symptoms such fatigue, weakness, shallow or rapid breathing, blue skin, convulsions, pale skin, or pale fingernails. All of these adverse impacts are hampering the market expansion.

COVID-19 Impact:

The COVID-19 pandemic had a tremendous influence on the healthcare systems, with serious ramifications for both COVID-19-infected patients and non-infected patients, leading to the cancellation of treatment and procedures to manage and reserve resources. The prevalence of anaemia in COVID-19 patients resulted in a rise in the need for iron therapy and other anaemia-related treatments.

The pediatric segment is expected to be the largest during the forecast period

The pediatric segment is estimated to have a lucrative growth. Children frequently struggle with an iron shortage. It can take several forms, ranging from a minor deficit to iron deficiency anaemia. A child's growth and development might be impacted by untreated iron deficiency. Children's iron deficiencies are usually caused by inadequate nutrition, fast development, and low birth weight. Raising diagnosis of haemoglobin and hematocrit are driving the segment's demand.

The oral iron therapy segment is expected to have the highest CAGR during the forecast period

The oral iron therapy segment is anticipated to witness the fastest CAGR growth during the forecast period, due to its high iron balance restoring capacity. To replenish iron reserves and normalise ferritin levels, oral iron treatment must be used for at least three to six months. By raising the body's iron and haemoglobin levels, it alleviates the patient's symptoms. Different levels of elemental iron are included in oral iron supplements.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to its developed healthcare system. The demand for iron deficiency anaemia treatments is increasing due to the region's developed healthcare infrastructure and the presence of significant market competitors. Additionally, expanding consumer awareness of women's health issues and technical improvements are propelling market expansion in this region.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the increasing population and government initiatives. This region has huge population of women. The market demand in this area is being driven by rising healthcare costs, government initiatives to support the healthcare sector, and growing demand for IDA treatment.

Key players in the market:

Some of the key players profiled in the Iron Deficiency Anemia (IDA) Therapy Market include: Vifor Pharma Ltd, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, Novartis AG, Mylan N.V., Lupin, Zydus Cadila, GlaxoSmithKline plc, Fresenius SE & Co. KGaA, F. Hoffmann-La Roche Ltd, Shield Therapeutics, Pharmacosmos A/S, AMAG Pharmaceuticals, Akebia Therapeutics, Inc, AbbVie Inc., Hikma Pharmaceuticals plc, Alkem Laboratiories, Advanz Pharmaceutical and Rockwell Medical, Inc.

Key Developments:

In February 2023, Rockwell Medical, Inc. announced that the Company signed a three-year product purchase agreement with Concerto Renal Services ("Concerto"), the largest provider of dialysis in skilled nursing facilities in the United States. Under the terms of the agreement, Rockwell Medical will be the primary supplier of liquid and dry acid and bicarbonate concentrates to Concerto through a three-year commitment that includes supply and purchasing minimums.

In September 2022, Alkem Laboratories announced that its off-the-shelf cell therapy product, StemOne has received regulatory approval from the Drug Controller General of India (DCGI) for its launch in India. The product, launched by Alkem Laboratories in collaboration with Stempeutics, is for the treatment of Knee Osteoarthritis, a degenerative disease of the joint.

In March 2022, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the launch of its first generic version of Revlimid®1 (lenalidomide capsules), in 5mg, 10mg, 15mg, and 25mg strengths, in the United States.

Therapies Covered:

  • Parenteral Iron Therapy
  • Oral Iron Therapy
  • Red Blood Cell Transfusion Therapy
  • Other Therapies

Therapy Areas Covered:

  • Congestive Heart Failure (CHF)
  • Renal, Obstetrics & Gynaecology
  • Oncology
  • Inflammatory Bowel Disease
  • Other Therapy Areas

Age Covered:

  • Geriatric
  • Adults
  • Pediatric

End Users Covered:

  • Clinics
  • Hospitals
  • Home Healthcare

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Iron Deficiency Anemia (IDA) Therapy Market, By Therapy

  • 5.1 Introduction
  • 5.2 Parenteral Iron Therapy
  • 5.3 Oral Iron Therapy
  • 5.4 Red Blood Cell Transfusion Therapy
  • 5.5 Other Therapies

6 Global Iron Deficiency Anemia (IDA) Therapy Market, By Therapy Area

  • 6.1 Introduction
  • 6.2 Congestive Heart Failure (CHF)
  • 6.3 Renal, Obstetrics & Gynaecology
  • 6.4 Oncology
  • 6.5 Inflammatory Bowel Disease
  • 6.6 Other Therapy Areas

7 Global Iron Deficiency Anemia (IDA) Therapy Market, By Age

  • 7.1 Introduction
  • 7.2 Geriatric
  • 7.3 Adults
  • 7.4 Pediatric

8 Global Iron Deficiency Anemia (IDA) Therapy Market, By End User

  • 8.1 Introduction
  • 8.2 Clinics
  • 8.3 Hospitals
  • 8.4 Home Healthcare

9 Global Iron Deficiency Anemia (IDA) Therapy Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Vifor Pharma Ltd
  • 11.2 Teva Pharmaceutical Industries Ltd
  • 11.3 Sanofi
  • 11.4 Pfizer Inc
  • 11.5 Novartis AG
  • 11.6 Mylan N.V.
  • 11.7 Lupin
  • 11.8 Zydus Cadila
  • 11.9 GlaxoSmithKline plc
  • 11.10 Fresenius SE & Co. KGaA
  • 11.11 F. Hoffmann-La Roche Ltd
  • 11.12 Shield Therapeutics
  • 11.13 Pharmacosmos A/S
  • 11.14 AMAG Pharmaceuticals
  • 11.15 Akebia Therapeutics, Inc
  • 11.16 AbbVie Inc.
  • 11.17 Hikma Pharmaceuticals plc
  • 11.18 Alkem Laboratiories
  • 11.19 Advanz Pharmaceutical
  • 11.20 Rockwell Medical, Inc

List of Tables

  • Table 1 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
  • Table 3 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
  • Table 4 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
  • Table 5 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
  • Table 6 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
  • Table 7 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
  • Table 8 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
  • Table 9 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
  • Table 10 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
  • Table 11 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
  • Table 12 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
  • Table 13 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
  • Table 14 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
  • Table 15 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
  • Table 16 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
  • Table 17 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
  • Table 18 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 19 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 20 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
  • Table 21 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
  • Table 22 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
  • Table 23 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
  • Table 24 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
  • Table 25 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
  • Table 26 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
  • Table 27 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
  • Table 28 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
  • Table 29 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
  • Table 30 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
  • Table 31 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
  • Table 32 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
  • Table 33 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
  • Table 34 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
  • Table 35 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
  • Table 36 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
  • Table 37 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
  • Table 38 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 39 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 40 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
  • Table 41 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
  • Table 42 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
  • Table 43 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
  • Table 44 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
  • Table 45 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
  • Table 46 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
  • Table 47 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
  • Table 48 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
  • Table 49 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
  • Table 50 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
  • Table 51 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
  • Table 52 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
  • Table 53 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
  • Table 54 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
  • Table 55 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
  • Table 56 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
  • Table 57 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
  • Table 58 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 59 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 60 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
  • Table 61 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
  • Table 62 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
  • Table 63 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
  • Table 64 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
  • Table 65 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
  • Table 66 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
  • Table 67 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
  • Table 68 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
  • Table 69 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
  • Table 70 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
  • Table 71 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
  • Table 72 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
  • Table 73 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
  • Table 74 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
  • Table 75 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
  • Table 76 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
  • Table 77 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
  • Table 78 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 79 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 80 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
  • Table 81 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
  • Table 82 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
  • Table 83 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
  • Table 84 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
  • Table 85 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
  • Table 86 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
  • Table 87 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
  • Table 88 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
  • Table 89 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
  • Table 90 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
  • Table 91 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
  • Table 92 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
  • Table 93 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
  • Table 94 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
  • Table 95 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
  • Table 96 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
  • Table 97 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
  • Table 98 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 99 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 100 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
  • Table 101 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
  • Table 102 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
  • Table 103 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
  • Table 104 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
  • Table 105 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
  • Table 106 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
  • Table 107 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
  • Table 108 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
  • Table 109 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
  • Table 110 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
  • Table 111 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
  • Table 112 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
  • Table 113 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
  • Table 114 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
  • Table 115 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
  • Table 116 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
  • Table 117 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
  • Table 118 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 119 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 120 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)